Trials / Completed
CompletedNCT02924402
Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies
A Phase 1 Multidose Study to Evaluate the Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-Expressing Hematologic Malignancies
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 154 (actual)
- Sponsor
- Xencor, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine the safety and tolerability of intravenous (IV) and subcutaneous (SC) administration of XmAb13676 and to determine the maximally tolerated dose (MTD) and/or recommended dose (RD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | XmAb13676 | Biological |
Timeline
- Start date
- 2016-10-01
- Primary completion
- 2024-04-01
- Completion
- 2024-04-01
- First posted
- 2016-10-05
- Last updated
- 2024-11-13
Locations
23 sites across 4 countries: United States, France, South Korea, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02924402. Inclusion in this directory is not an endorsement.